Prosecution Insights
Last updated: April 19, 2026

Fusion Pharmaceuticals Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17337358 RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY VALLE, ERNESTO 1623 Final Rejection Jun 02, 2021
17337357 RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY VU, JAKE MINH 1618 Final Rejection Jun 02, 2021
16619433 RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY CRAIGO, BAHAR ALAWI 1699 Non-Final OA Dec 04, 2019

Managing Fusion Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month